English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Ashwagandha After Menopause: What a New 12-Week Trial Actually Found
You can follow every rule in the book — eat clean, walk daily, cut the wine, keep the phone out of the bedroom — and still find yourself staring at the ceiling at 3 a.m., damp sheets and racing thoughts, wondering what happened to the person who used to sleep through anything. Post-menopause life has its own weather system. Hot flashes crash in without warning, sleep frays at the edges, and body fat starts parking itself in places it never used to. So it's not surprising that a lot of women in their late forties and fifties are quietly experimenting with adaptogens. Ashwagandha — a root that's been used in Ayurvedic medicine for centuries — has become the darling of the wellness aisle, mostly for stress and sleep. But a recent randomized clinical trial asked a more interesting question: could it also help with the specific tangle of symptoms that menopause hands you? The trial was modest but properly designed. Researchers recruited 66 postmenopausal women between the ages of 45 and 65 and split them into two groups. One group took 600 milligrams of a standardized ashwagandha root extract every day for twelve weeks. The other group took a placebo. Neither the women nor the researchers knew who was getting what until the study wrapped — the gold-standard double-blind setup. Over those three months, the team tracked a lot of variables. Sleep quality. The severity of menopause-related symptoms. Body composition, meaning shifts in muscle and fat percentages. Quality of life across physical, emotional, and social domains. They even measured bone mineral density, curious whether the herb might nudge that needle too. Three participants dropped out along the way, leaving 63 women who completed the full protocol. Sleep was the standout. Women taking ashwagandha reported meaningfully better sleep quality by the end of the trial, while the placebo group barely moved. That tracks with what a lot of ashwagandha users anecdotally report — it doesn't knock you out like a sedative; it just seems to soften the edges enough that sleep comes more easily and stays longer. Menopause symptoms improved too, and by a wider margin than placebo. Quality-of-life scores climbed in several categories. Body composition shifted slightly in the ashwagandha group's favor — body-fat percentage ticked down, while it drifted up in the placebo group. Bone density didn't budge in either group, but that's not shocking. Meaningful bone changes usually take a year or more to show up on a scan. Twelve weeks is a blink for a skeleton. Side effects? Minimal. No serious adverse events were reported, and the supplement was generally well tolerated. Which is roughly consistent with ashwagandha's broader safety record in short-term use. Here's where the enthusiasm needs a slight cooling. The study was small — 63 women is enough to detect a signal, but not enough to declare victory. Everyone came from a single research center in Amritsar, India, which means we don't yet know whether the results generalize to women with different diets, genetics, activity levels, or hormonal histories. The twelve-week window is another honest limitation. It's plenty of time to catch changes in sleep and mood. It's not nearly long enough to tell us whether the fat-loss trend continues, whether bone health eventually improves, or whether the sleep benefits hold up at month six or twelve. And the study doesn't explain the mechanism — we don't really know why ashwagandha seems to help with these particular symptoms, only that in this group, for this duration, it did. One more thing that gets glossed over in most write-ups: the trial used a specific standardized root extract at 600 mg. Ashwagandha supplements on the shelf are a wild west of extract types, dosages, and quality-control standards. A cheap capsule of ground root powder is not the same product as a concentrated, standardized extract. If you want to replicate what the study measured, you need to read labels carefully. Adaptogens like ashwagandha have crossed over from Ayurvedic tradition into mainstream wellness in a way that mirrors, in a smaller and gentler register, the mainstreaming of plant medicines more broadly. People are increasingly willing to look outside the pharmacy for tools to manage stress, sleep, mood, and the messy transitions of midlife. That's mostly a healthy trend. But it comes with a responsibility to actually look at the evidence rather than the marketing. Ashwagandha isn't a psychedelic and it isn't a hormone. It's a plant compound that appears, based on a growing but still limited body of research, to gently support the stress-response system — the HPA axis, cortisol regulation, that whole cascade. That's the plausible mechanism behind why it might help with sleep and menopause symptoms, since both are tangled up with how the body handles stress signals. Whether or not you decide to try ashwagandha, the boring fundamentals still matter more than anything you'll find in a bottle. If sleep and body composition are what you're chasing, these move the needle: This trial is a promising lead, not a case closed. Ashwagandha may be a quiet multitasker for post-menopausal women — helping with sleep, easing symptom load, nudging body composition in a favorable direction — but we're going to need larger, longer, more diverse studies before we can say that with real confidence. Treat it as one small tool, not a fix. For readers who are drawn to plant-based approaches to healing and want to explore that world more deeply — retreats built around traditional plant medicines, contemplative practice, and integration work — a curated selection can be browsed on our marketplace here. The bigger point is the same either way: the plants are only ever part of the answer. What you do with the rest of your life is the other part, and usually the more decisive one.
Ibogaine for Opioid Addiction: What the ARPA-H Push Means for Recovery
Something quietly historic happened in Washington this month. The Advanced Research Projects Agency for Health — ARPA-H, the federal outfit modeled on the Pentagon's DARPA but pointed at biomedical problems — convened a room full of researchers, clinicians, and pharma people to talk about ibogaine. Not whether to study it. How to study it, fast, and get it through the FDA gauntlet as a treatment for opioid use disorder. If you've been following the psychedelic and plant-medicine space for any length of time, you know how strange that sentence is. Ibogaine has spent decades as the underground option — the one desperate families whispered about when methadone stopped working and their kid was overdosing again. Now it's the subject of a formal government funding call, with a program name (ASCENT-IBO) and a proposal deadline. The signal that sends is worth unpacking, especially if you or someone you love is weighing a trip to Mexico or Costa Rica for treatment. The workshop was what's called a Proposers' Day — a matchmaking event where potential research teams pitch ideas, meet collaborators, and get a read on what the funder actually wants. ARPA-H is looking for clinical studies of ibogaine, with a preference for combined Phase I/II designs and a real plan for what comes after. Proposals are due in mid-October, which by government standards is a sprint. The framing the agency has been using — move fast, with precision — tells you where they sit. They don't want another decade of underpowered pilots and academic squabbles. They want data that could plausibly support an FDA approval pathway. That's a very different posture from the cautious, we'll-see-in-fifteen-years approach that has defined most psychedelic drug development. The urgency isn't hard to explain. Opioid overdose deaths in the United States have hovered near or above 80,000 a year for most of the last half-decade. The existing standard of care — methadone, buprenorphine, naltrexone — works for some people, but a huge cohort either can't tolerate it, relapses on it, or refuses to start it in the first place. Ibogaine's promise is that a single dose, delivered in a controlled setting, can dramatically reduce or eliminate opioid withdrawal and cravings. If even a fraction of the anecdotal reports hold up under rigorous study, the public-health implications are massive. People sometimes lump ibogaine in with ayahuasca, psilocybin, and other plant medicines, and while there's overlap in the broader category of psychedelic-assisted recovery, ibogaine is its own animal. It comes from the root bark of the iboga shrub, native to West Africa, where it's been used in Bwiti spiritual practice for generations. Chemically, it hits a wider range of receptors than most classical psychedelics — including opioid receptors themselves — which is part of why it seems to interrupt addiction so effectively. The experience is also distinctive. Where an ayahuasca ceremony might run four to six hours with waves of visionary content, an ibogaine session can last twenty-four to thirty-six hours. People describe it less as a mystical journey and more as an unblinking review of their own life — a kind of forced life audit, often unpleasant, sometimes revelatory. It's not recreational. Nobody does ibogaine for fun. Here's the part that matters for anyone considering it: ibogaine carries real cardiac risk. It can prolong the QT interval in the heart's electrical cycle, and there have been deaths, mostly in unscreened or under-monitored settings. This is precisely why federal-grade clinical infrastructure matters. A properly run study — or a properly run retreat — screens participants with an EKG, checks electrolytes, monitors continuously, and has emergency protocols in place. An underground provider working out of a rented villa may not. Short answer: not immediately, but meaningfully over the next few years. Ibogaine remains a Schedule I substance in the United States, meaning it's illegal to possess or administer outside of federally approved research. The ARPA-H push doesn't change that overnight. What it does is create the clinical evidence base that regulators need to eventually reschedule the compound and approve it as a prescription medicine — probably in a highly controlled, in-clinic model similar to what we're seeing proposed for MDMA and psilocybin. For people who can't wait — and if you're in active opioid use disorder, waiting is not a neutral choice — the current options are legal treatment clinics in Mexico, Costa Rica, Portugal, Brazil, and a handful of other jurisdictions. Some of these are excellent. Some are dangerous. Telling them apart is the single most important task in front of you if you're heading this direction. What to look for when evaluating an ibogaine provider: Zoom out and the ARPA-H announcement fits a pattern. Over the last few years, master plants and the compounds derived from them — ayahuasca, psilocybin, ibogaine, mescaline, DMT — have been slowly pulled out of the countercultural margins and dropped onto the desks of federal health officials, VA researchers, and mainstream psychiatric journals. The framing has shifted from "drug of abuse" to "underused therapeutic tool." That shift isn't complete, and it isn't guaranteed to continue. But the direction is clear. What's interesting about the ibogaine case specifically is that the traditional and the clinical worlds are being forced into conversation. The Bwiti practitioners in Gabon have known for a very long time that this root does something profound. The cardiologists at ARPA-H are now asking, essentially, how to deliver that something safely at scale. Neither community has the complete answer on its own. The retreats and clinics that seem to get the best outcomes tend to borrow from both — Western medical safety on the outside, ceremony and psychological depth on the inside. If you're reading this because you're stuck — because standard treatment hasn't worked, or because you've watched someone you love cycle through detox after detox — the honest thing to say is that ibogaine isn't magic and it isn't for everyone. It's a serious intervention with serious risks and, in the right hands, remarkable potential. The fact that a federal agency is now willing to say that in public, and put money behind it, matters. If your interest is clinical, keep an eye on the ASCENT-IBO trials as they get funded and enrolled over the next year or two. Participating in a formal study, when one is available in your area, is the safest and cheapest way to access ibogaine legally in the U.S. If your interest is more immediate, do the slow work of researching international providers — read the alumni forums, talk to people who've been through the doors, and don't let urgency override due diligence. A bad ibogaine experience isn't a bad weekend. It can be a life-altering event, in either direction. For readers wanting to explore the current landscape of ibogaine and other plant-medicine recovery programs more directly, a curated selection of screened retreats can be browsed on our marketplace here. Whatever route you take, take it with your eyes open, your medical history in hand, and someone in your life who knows where you'll be and when you're expected home.
Mental Fitness vs. Mindfulness: Is the Rebrand Helping or Hurting?
Scroll through any wellness feed lately and you'll notice something odd. We're not really being told to meditate anymore. We're being told to train. To strengthen focus. To build mental fitness. The word mindfulness still shows up, sure, but it's often riding shotgun to a more muscular vocabulary — one borrowed straight from the gym. It's a subtle shift, but a real one. And if you've been sitting on a cushion (or thinking about sitting on one) for any length of time, it's worth asking what's actually happening here. Are we talking about the same practice with new packaging? Or are we quietly changing what meditation is supposed to do? Mindfulness has an image problem in certain rooms. Say the word in a boardroom, a barracks, or a locker room and you'll get raised eyebrows — maybe a joke about crystals. For plenty of people, the term still carries a whiff of incense and vague spirituality, which makes it a hard sell in cultures built on measurable performance. Enter mental fitness. Same underlying tools, mostly. But the framing lands differently. Fitness implies training, effort, a goal you're moving toward. It doesn't ask you to believe anything. It just asks you to show up and do the reps. For a lot of people who'd never book a meditation retreat, that reframing is the difference between trying it and dismissing it outright. Researchers working with the U.S. Army have leaned into this deliberately. When designing contemplative programs for senior military leaders, some instructors have swapped out traditional language for terms like attentional fitness. The reasoning is practical: soldiers won't engage with something that sounds unscientific or quasi-religious, but they'll absolutely train an attention muscle if you frame it like PT. Here's where it gets interesting. When you call something fitness, you're making a claim about outcomes. Push-ups aren't the goal — the chest muscles are. Running isn't the goal — cardiovascular endurance is. The activity is a means; the capacity is the end. Apply that logic to the mind and mindfulness becomes the exercise, while things like focus, emotional regulation, and cognitive flexibility become the muscles. One retired Army general puts it in language his soldiers understand: he calls the practice “zero the mind,” a nod to zeroing a weapon — the process of aligning the sights so your aim matches where the round actually lands. That metaphor does a lot of work in a room that would otherwise tune out. And there's science backing the idea that the tools deliver measurable capacities. A large meta-analysis of more than 100 randomized controlled trials, covering roughly 9,500 participants, found that mindfulness-based interventions produced small-to-moderate improvements across executive attention, sustained attention, working memory, inhibition, and cognitive flexibility. So the fitness framing isn't lying to anyone. The reps really do build something. But — and this is the part that gets under my skin a little — the fitness frame changes the relationship you have with the practice itself. Traditional mindfulness is fundamentally about noticing. You sit, you watch what the mind does, you notice when attention drifts, you come back. There's no scoreboard. There's no personal best. The instruction is famously irritating in its simplicity: notice without judgment. Not notice-in-order-to-fix. Not notice-so-you-can-optimize. Just notice. Fitness language quietly reintroduces the scoreboard. If you're building something, you'll naturally want to measure it. Am I more focused this week? Am I calmer under pressure? Am I getting my money's worth from the twenty minutes I sat this morning? Those questions aren't bad — but they're a different game than the one meditation was originally teaching. One researcher looking at metaphor and the mind flagged phrases like optimize your focus, master your emotions, and organize your thoughts as examples of a broader trend: framing the inner life as something to be managed. And when your inner life becomes a project, it's very hard not to grade yourself on it. Anyone who's spent time around ayahuasca, psilocybin, or other plant-medicine work will recognize this tension immediately. Retreat culture has its own version of the same drift — the pressure to come home from ceremony with a clear takeaway, a life lesson, a specific insight you can plug into your Notion doc. The medicine, though, rarely cooperates on that timeline. Most facilitators I've spoken with — the ones who've been doing this for decades, not the ones with a shiny website and a booking calendar — will tell you the same thing: the work isn't about performance. It's about what you're willing to see. Sometimes what you see doesn't have a use. Sometimes it just changes you slowly, in ways you can't measure for a year. A daily mindfulness practice actually pairs beautifully with plant-medicine work for exactly this reason. Both ask you to build the capacity to sit with what arises without immediately trying to fix, escape, or optimize it. If your meditation practice has trained you to grade every session, you'll walk into ceremony wanting a grade there too. And that's usually where people get stuck. I don't want to be too precious about this. The mental fitness framing is genuinely opening doors that mindfulness alone couldn't push through — soldiers, executives, athletes, first responders, plenty of people who'd never touch a Buddhist-flavored intro course are now practicing something real. That matters. Getting more people to actually train their attention is a net good for the world. At the same time, the frame matters. Consider holding both: The old teachers had a phrase for this — practice without gaining idea. Sit, but don't sit for anything. That instruction sounds absurd in a culture obsessed with ROI, which is probably why it's still worth passing on. If you're new to any of this — meditation, plant medicine, contemplative work of any kind — a few honest suggestions: None of this is meant to knock the people rebranding mindfulness for new audiences. They're doing important work, and language that lands is language that gets used. The invitation is just to notice — quietly, without making a project of it — when the frame starts to swallow the practice. For readers ready to take contemplative or plant-medicine work beyond the app on their phone, a curated range of meditation and psychedelic retreats can be browsed on our marketplace here. Whichever door you walk through, the practice underneath is older than any of the words we've come up with for it.
Psychedelic Drug Development in 2026: What the Latest Trials Mean for Retreat-Seekers
If you've been quietly researching an ayahuasca or psychedelic retreat, you've probably noticed something odd happening in parallel: the pharmaceutical world is now racing to bottle up the same molecules — psilocybin, ibogaine, DMT — that retreat centres have worked with for years, sometimes centuries. Two worlds, same compounds, wildly different framings. I want to walk through the most recent wave of clinical news, because it actually matters for anyone considering a plant-medicine journey. Not because a retreat is the same as a Phase 3 trial — it definitely isn't — but because the research shapes public understanding, legal access, and the kind of conversations you'll end up having with your doctor, your family, and yourself. Here's what's happening, translated out of biotech-speak. Compass Pathways, one of the more visible companies developing a synthetic psilocybin product (they call it COMP360), just released one-year follow-up data from a Phase 3 trial in treatment-resistant depression. The trial enrolled 258 people who hadn't responded to standard antidepressants. Half received a 25 mg dose of psilocybin, half got placebo, and the study followed them through several phases: a blinded six-week window, a longer twenty-week window with a possible second dose, then an open-label stretch where anyone still struggling could receive an active dose. Around 70% of participants moved into that final open-label phase — which itself tells you something. It means the initial single dose helped some people meaningfully, but plenty of others either relapsed or didn't respond enough to feel done. The headline finding: people who received the active dose early on, plus another dose later, showed roughly a 13-point drop on the MADRS depression scale at the one-year mark. That's clinically meaningful. It's not a cure. It's a real, measurable shift held over twelve months in people whose depression hadn't budged for anything else. What does this mean for you as someone considering a retreat? A few things. First, psilocybin's antidepressant effect appears durable for a substantial subset of people — but repeat exposure seems to matter. The old story that "one journey and you're fixed" was always oversold. Many retreat centres already know this; it's why serious ones offer multi-day ceremonies and integration coaching. Second, dropouts and non-responders exist in every study, and they exist at retreats too. If someone promises you a guaranteed outcome, they're either naive or lying. Ibogaine — the West African root-derived psychedelic used for opioid and stimulant addiction — has spent decades in a strange twilight: illegal in the U.S., celebrated by a small network of clinics in Mexico and Central America, and quietly credited by many people in recovery for saving their lives. Recently that changed. U.S. Health Secretary Robert F. Kennedy Jr. hosted Dimitri Mugianis (well-known in the harm-reduction and ibogaine advocacy world) and other voices calling for federal research funding. Congressman Doug Collins spoke about ibogaine on cable news. A supplier filed a citizen petition with the FDA. The word ibogaine is now being said out loud in rooms where it used to be whispered. Why does this matter for the addiction-recovery reader? Because access is shifting. Texas allocated $50 million to ibogaine research. The Department of Veterans Affairs is quietly interested. If you or someone you love is looking at ibogaine specifically for opioid dependence or alcoholism, you're no longer operating in complete regulatory darkness. That's good news. It also means the sketchy end of the ibogaine world — unlicensed operators, thin medical screening, no cardiac monitoring — is about to get more competition from clinical settings. Ibogaine can stop the heart of the wrong candidate. Cardiac screening is non-negotiable. Any provider who waves that requirement off is a provider you walk away from. Ayahuasca sits in an interesting spot: it's the plant medicine getting the most cultural attention from retreat-seekers, and simultaneously the least pharmaceutical action. There's no ayahuasca Phase 3 trial. There's no synthetic "ayahuasca product" being filed with the FDA. Companies like Definium and others are working with DMT (one of ayahuasca's key components) in isolated, injected form for anxiety — but that's a different animal. Injected DMT is a fifteen-minute experience in a clinic. Ayahuasca in ceremony is a four-to-six-hour journey guided by a curandero who spent decades apprenticing with the vine. What this means, practically: if ayahuasca calls to you, the retreat path isn't going to be replaced by a pill any time soon. The ceremonial container — the icaros, the diet, the group setting, the master plants beyond the brew itself — is not something a pharmaceutical company can bottle. That's a feature, not a bug. It also means the responsibility of finding a legitimate, safe, well-run ayahuasca retreat still falls squarely on you. Here's the thing about biotech announcements — they're written for investors, not for you. When you see headlines about approvals, trials, and acquisitions (Eli Lilly just closed its purchase of AtaiBeckley, folding another psychedelic developer into big pharma), the story is really about market timelines, share prices, and regulatory strategy. It's not necessarily about whether psychedelics work. That question has been answered in dozens of smaller trials for years. A few things to keep in mind when the psychedelic news cycle gets loud: The clinical progress is genuinely encouraging, but it doesn't replace the questions you need to sit with before booking. Are you working with a therapist? Have you told your doctor about any SSRIs or other medications you're on? Do you have someone at home who knows where you're going and can help you land afterwards? Integration — the weeks and months after — is where the actual life change happens, or doesn't. Retreats that don't offer integration support are selling you half the product. Choose based on lineage, not marketing. A good ayahuasca centre will tell you who its curanderos apprenticed with. A good ibogaine clinic will hand you a cardiac screening checklist before you've even asked. A good psilocybin retreat will explain, in plain language, what happens if you have a hard journey. Vague websites full of stock photos and buzzwords about "transformation" are a red flag. Specificity is a green flag. We're living through a strange convergence. Ancient plant-medicine practices, dismissed by Western medicine for a century, are now being validated in the highest levels of the pharmaceutical world — even as the actual retreat and ceremony space keeps doing its quiet work, largely unchanged. Both paths have value. Both have risks. Neither is the whole answer. If you're reading this because you're stuck — in addiction, in depression, in a life pattern you can't shake — the news that psilocybin held its antidepressant effect for a year in a rigorous trial is meaningful. So is the fact that ibogaine is finally getting mainstream political attention. So is the reality that thousands of people have found meaningful shifts through ceremonial ayahuasca work with skilled facilitators, long before any of this made the news. For readers who want to take the next step, a curated range of ayahuasca and psychedelic plant-medicine retreats can be browsed on our marketplace here. Take your time. Ask hard questions. The right retreat is the one that respects both the medicine and you.
Choosing Therapy Tools by Process: A Guide for Psychedelic Integration Work
Here's something most integration therapists figure out about six months in: the tidy therapeutic camps you learned about in grad school — CBT over here, ACT over there, DBT in its own corner — start to look less like separate disciplines and more like different hallways leading to the same handful of rooms. And when you're working with someone who just came back from an ayahuasca retreat, or a psilocybin ceremony, or an ibogaine detox, that realization matters more than usual. Because the person sitting across from you isn't showing up with a neat DSM diagnosis. They're showing up with something cracked open. This piece is for the therapists, coaches, and facilitators doing integration work after psychedelic experiences — and honestly, it's also for the retreat-goers themselves, who deserve to know how the good ones actually think. The idea is simple: choose your tools based on the psychological process a person needs shifted, not based on which brand of therapy you happened to study first. In the world of plant medicine and psychedelic healing, where clients arrive with radically different needs from week to week, this flexibility isn't optional. It's the job. Training programs love camps. You're a CBT person, or you're an ACT person, or you're doing internal family systems, or you're a somatic experiencing practitioner. Each tradition has its own jargon, its own founder-heroes, its own conferences. And each one, quietly, implies that mixing tools from other schools is a bit sloppy — the mark of someone who hasn't fully committed. The result? A lot of therapists lean on the same three or four techniques for every client that walks in, because those are the techniques they learned first. That's fine if every client needs the same thing. They don't. Especially not the ones coming out of a psychedelic experience. Someone integrating a difficult DMT breakthrough needs something different from someone processing an ibogaine flood dose that surfaced twenty years of buried addiction memories. Someone whose San Pedro ceremony gave them a clear vision of their values needs something different from someone who came home from ayahuasca disoriented and can't stop crying at odd moments. The protocol lens flattens all this. The process lens does not. Think about cognitive restructuring — the classic CBT move where you catch an ugly thought and interrogate it against evidence. Then think about cognitive defusion in ACT, where instead of arguing with the thought, you learn to watch it float by like a leaf on a stream. Different vocabulary, different theory of change. But if you squint, both are doing the same thing: creating some breathing room between the client and the sticky mental content that's causing them grief. Neither one is better in the abstract. Which door works depends on the person in front of you — their history, their moment, what's already been tried. This insight is what powers the process-based therapy movement, which argues that we should organize treatment around the mechanisms that maintain suffering (rigid thinking, avoidance, emotional dysregulation, disconnection from meaning) rather than around diagnostic labels or brand-name protocols. For anyone doing psychedelic integration, this framing is a gift. Plant medicines don't respect diagnostic categories. They loosen everything at once. The person you're helping might need cognitive work one week and pure somatic regulation the next. Being fluent across traditions isn't disloyal to your primary training — it's the only honest way to meet what shows up. Below are five core psychological processes worth knowing well, with notes on when each one tends to matter most in the context of psychedelic healing and recovery from things like addiction, depression, or trauma. Master plants — ayahuasca, iboga, San Pedro, psilocybin — have a way of surfacing material across all five at once. Your job is to notice which lever is calling loudest today. Reach for this lever when a client is caught in a story. Maybe it's the harsh self-talk that survived even a beautiful ceremony intact. Maybe it's a rigid belief the medicine seemed to loosen and then, weeks later, snapped back into place. Cognitive restructuring — writing the thought down, testing it against real evidence, drafting a more balanced version — remains a workhorse here. So does the ACT move of prefacing every heavy thought with, I'm having the thought that… It's a small linguistic shift, but it puts a millimeter of space between the person and the content. In integration work, that millimeter is often enough. Sometimes the insight is already there. The person came back from their retreat knowing exactly what needs to change — the job they should leave, the relationship they should end, the substance they should stop using. And then, three weeks later, nothing has moved. This is the gap between knowing and doing, and it's where behavioral levers earn their keep. Behavioral activation — scheduling meaningful action before the client feels ready — rests on the counterintuitive bet that motivation follows action, not the other way around. Motivational interviewing works the opposite side of the same coin, meeting a client's ambivalence head-on and drawing out their own reasons for change. Both are useful. Which one to pick depends on whether your client needs a nudge into the water or a conversation on the shore first. Post-ceremony emotional weather can be wild. Waves of grief, flashes of joy, sudden numbness, panic that arrives without warning. The window of tolerance framework — mapping the zone between hyperarousal and hypoarousal — gives clients a shared language for what's happening in their nervous system. Once they can name the zone they're in, they can start choosing from a menu of regulation tools: breathwork, cold water, movement, grounding practices, phone-a-friend protocols. This is also where somatic approaches often outperform cognitive ones. You can't think your way out of a dysregulated nervous system. You have to work with the body. Anyone doing serious integration work should have at least a few embodied techniques in the kit, even if talk therapy is their home base. Psychedelics famously do something to values. People come out of ceremonies with a burning clarity about what actually matters — and then, gradually, real life sands that clarity down. The values lever is about protecting the signal before it fades. ACT gives you structured maps like the hexaflex, which let clients look directly at what they care about and where their behavior is or isn't aligned. Positive psychology's more playful moves — the “what would you do if you couldn't fail” question, letters from your future self, imagined eulogies — sneak up on the same territory through the side door. Both work. Some clients want the map. Some clients need the story. Finally, there's the lever most integration work under-uses: reconnecting people with what they're already good at. Someone coming out of addiction recovery has often spent years marinating in a story about their own brokenness. The medicine may have briefly shown them a different picture — a capable, curious, kind version of themselves — but that image is fragile. Strengths work makes it durable. Character-strength assessments give clients a vocabulary for what they bring. Follow-up work looks at overuse and underuse — because a strength wielded carelessly (relentless perseverance, say, or bottomless kindness) can become the very thing that keeps someone stuck. Both moves matter. A few things I've noticed help therapists shift from protocol thinking to process thinking: If you're on the other side of this — a person weighing whether to book an ayahuasca or psilocybin retreat — the takeaway is this: the medicine is only half the equation. The integration is the other half, and the quality of your integration support depends heavily on whether the therapist or coach you work with can think flexibly across processes. Ask them. A good one will happily explain how they choose their tools. A rigid one will name their tradition and stop there. The retreats themselves vary wildly on this front too. Some hand you a certificate and wave goodbye at the airport. Others build integration into the container from the start — group calls, one-on-one sessions, a follow-up arc that lasts months. The difference in long-term outcomes between these two models is not subtle. If you're doing this to work on addiction, trauma, or something else with real stakes, integration quality should be near the top of your criteria list. For readers who want to take this further, a range of curated ayahuasca and plant-medicine retreats — including several that take integration seriously — can be browsed on our marketplace here. Whatever you choose, choose the whole arc, not just the ceremony.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Plant Variety and Colon Cancer: What a New Phytochemical Study Suggests
Think back to what you actually ate yesterday. Not what you meant to eat — what actually landed on the plate. A handful of blueberries with your oats? A side salad you almost skipped? Lentils in a soup, some pumpkin seeds on top, maybe a mug of green tea while you answered emails? If any of that sounds familiar, you were quietly loading up on phytochemicals — the compounds plants make to protect themselves that seem to do useful things for us too. A study published earlier this year put a striking number on the payoff. People whose diets scored highest for phytochemical-rich foods had roughly 52% lower odds of colorectal cancer than people whose diets scored lowest. That’s the kind of headline that deserves both attention and a little skepticism, so let’s unpack it — and then talk about why any of this matters if you’re preparing for a plant-medicine retreat, coming home from one, or just trying to eat like you mean it. The study compared 980 adults — half diagnosed with colorectal cancer, half not — and asked them to fill out detailed food questionnaires. From those answers, researchers calculated something called a Dietary Phytochemical Index, a score that estimates how much of a person’s daily calorie intake comes from plants rich in these protective compounds. Phytochemicals aren’t a single thing. The umbrella covers polyphenols, flavonoids, carotenoids, phytosterols, and a long tail of lesser-known compounds. You’ll find them in berries, leafy greens, beans and lentils, whole grains, nuts, seeds, herbs, spices, cacao, coffee, and tea. Different plants carry different mixes, which is why nobody serious in nutrition science is still hunting for one heroic superfood. The highest-scoring participants didn’t just have lower cancer odds. They also showed friendlier markers of inflammation and oxidative stress — two processes that turn up over and over in research on chronic disease. The obvious caveat: this is an observational study. Some participants already had cancer when their diets were measured, so we can’t say the phytochemicals prevented anything. What we can say is that a pattern keeps showing up, in study after study, and it’s pointing in the same direction. Here’s the thing the wellness industry keeps getting wrong: it wants a hero. One berry. One mushroom. One powder in a $60 tub. The research just doesn’t cooperate. What consistently helps is the range of plants someone eats over a week, not the intensity of any one item. The reason is chemical. Blueberries bring anthocyanins. Broccoli brings sulforaphane. Turmeric brings curcumin. Green tea brings catechins. Black beans bring their own polyphenol profile. Each compound seems to do slightly different work in the body — some are antioxidants, some modulate inflammation, some feed the specific gut bacteria that keep the colon lining calm. Eat only one of them and you get one narrow slice of the benefit. Rotate through many and the effects appear to stack. There’s a rough goal that keeps popping up in gut-health research: thirty different plant foods a week. That sounds like a lot until you count herbs, spices, nuts, seeds, and beans — a bowl of chili with cumin, cilantro, onion, garlic, tomatoes, kidney beans, black beans, and a squeeze of lime is already eight before you’ve touched a vegetable side. You don’t need a spreadsheet or a supplement stack. You need a slightly wider rotation and slightly less autopilot at the grocery store. A few honest starting points: The goal isn’t perfection. It’s exposure. You’re trying to feed a wider bacterial community in your gut and hand your body a broader set of raw materials, not audition for a magazine cover. If you’re here because you’re researching ayahuasca, San Pedro, or a psilocybin retreat, the phytochemical conversation should actually be interesting to you. Traditional ayahuasca dieta — the food restrictions the shipibo and other Amazonian traditions ask participants to follow — tend to strip the plate down to simple, bland foods: plantain, rice, some fish, boiled vegetables. Salt, sugar, fermented foods, pork, alcohol, and aged foods usually come off the table for a stretch. There are safety reasons (the MAOI activity in the ayahuasca brew makes certain foods risky) and there are ceremonial reasons (the fewer competing inputs, the clearer the plant’s voice, in the traditional view). But the dieta ends. Integration doesn’t. In the weeks after a ceremony, when the emotional cracks are still open and the nervous system is recalibrating, what you feed yourself matters more than usual. Chronic inflammation dulls mood, disrupts sleep, and clouds the kind of insight-work integration depends on. Loading the post-retreat weeks with colorful plants, plenty of fiber, and a wide phytochemical rotation isn’t just cancer-risk arithmetic — it’s giving your gut, your mood, and your brain the substrate to actually consolidate whatever you saw in ceremony. And on the other side, the pre-retreat window is a good moment to start too. Facilitators often ask participants to reduce processed food, alcohol, sugar, and caffeine in the two to four weeks before a retreat. That’s an opening. Fill the gap with variety rather than deprivation and you arrive lighter, clearer, and less likely to spend the first ceremony purging a week of drive-through. A 52% reduction in odds sounds enormous, and it is — but odds ratios in observational studies always deserve a second look. The people who eat the widest range of plants also tend to move more, sleep better, smoke less, and drink less. Statisticians try to adjust for those factors, but no adjustment is perfect. So treat the number as a strong signal, not a promise. What makes this line of research trustworthy isn’t any single study. It’s the consistency. Population studies, mechanistic lab work on individual phytochemicals, and gut-microbiome research keep converging on the same story: diverse plant intake is protective across a range of chronic diseases, and colorectal cancer is one of the clearest examples. The exact size of the effect will vary from study to study. The direction doesn’t. Nobody’s asking you to become vegan or memorize a list of flavonoids. The suggestion is smaller and more doable: widen the rotation. Add one new plant food to the shopping list this week. Put seeds on things. Drink tea. Cook with more herbs. The gut and the brain are more connected than most people were taught — take care of one and the other tends to thank you. For readers whose interest in this stretches beyond diet into deeper healing work, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here — many of them build nutrition, dieta, and integration meals directly into the program. Whatever you decide, the plate in front of you tonight is a fine place to start.
The Case for Presence: Why Mindfulness Matters Before and After Plant Medicine
Peel an orange. Actually peel it. Smell the oil that sprays out when your thumbnail breaks the skin. Look at the segments before you eat them. Notice the small explosion in your mouth when your teeth press down. If that sounds absurdly slow, ask yourself what you were planning to do with those ninety seconds instead — probably scroll, probably worry, probably nothing you'll remember by tomorrow. This is the strange thing nobody tells you when you start researching an ayahuasca retreat, an ibogaine program, or a psilocybin week in the mountains: the medicine is not the point. The medicine is a magnifier. What it magnifies is your capacity to actually be where you are. And that capacity — presence, attention, whatever you want to call it — is something you can start building today, for free, with a piece of fruit. People book plant-medicine retreats hoping for a breakthrough. Sometimes they get one. But the participants who seem to walk away genuinely changed — the ones whose marriages improve, whose drinking stops, whose depression finally lifts its foot off their chest — tend to share one quiet skill. They know how to sit with what's in front of them without immediately running. Ayahuasca will show you things. San Pedro will crack you open. Psilocybin will loosen the joints of your worldview. None of that matters if you spend the following weeks half-present, thumbing through your phone, replaying old arguments in your head, and generally continuing the exact patterns you paid several thousand dollars to interrupt. The ceremony is a doorway. Mindfulness is what lets you actually walk through it and then keep walking. This is why the best facilitators I've met talk almost as much about breakfast as they do about the brew. What you do with your ordinary hours is what determines whether the extraordinary ones stick. Let's strip the word down. Mindfulness is being here — body and mind in the same place, at the same time, aware of what's actually happening. That's it. No cross-legged posture required. No Sanskrit. You can be mindful cutting carrots. You can be mindful cleaning the toilet. (Yes, really. The toilet is a great teacher because nobody romanticises it.) The old-school Vietnamese Zen framing puts it beautifully: bringing the mind home to the body. Most of us walk around like ghosts of ourselves — the body is at the kitchen sink, but the mind is in a meeting three days from now, or in a fight from 2019, or in some vague fog of dread. Mindfulness is the practice of noticing that split and gently closing it, again and again, thousands of times a day if you can manage it. What grows from that practice is concentration. And concentration, if you let it deepen, produces insight — the kind of quiet clarity where you suddenly understand something about your own behaviour that no amount of thinking-hard has ever produced. Every plant-medicine tradition worth trusting is really teaching this same rhythm. The ayahuasca, the mushroom, the peyote button — they force the rhythm on you for a night. The rest of your life, you have to build it yourself. Here's a practical answer to something people search constantly: how do you actually prepare for an ayahuasca ceremony, or any serious psychedelic retreat, in the weeks beforehand? Yes, you follow the dieta the facilitators send. Yes, you cut out the pork and the sex and the SSRIs (on medical guidance — never just quit a psychiatric medication because a website said so). But the deeper preparation is training your attention. Try this for the two weeks before you fly out: People show up to their first ceremony wired, jet-lagged, and expecting the medicine to do all the work. It won't. Or rather, it will — but you'll be too scattered to receive most of what it offers. The participants who arrive already able to sit still get much more from the experience. This is not a secret. It's just rarely said out loud. Integration is the word everyone uses now, and it's mostly gone fuzzy from overuse. Here's what it actually means: taking the raw material a ceremony hands you and building a different life out of it. That building happens in the ordinary hours — the breakfast, the commute, the awkward phone call with your father, the walk to the corner store. If you can bring even a scrap of presence into those hours, the ceremony continues working. If you can't, the insights fade within weeks and you find yourself booking another retreat, hoping this one will finally stick. I've watched this pattern for years. The people who consume plant medicine as a series of peak experiences tend to stay stuck. The people who treat it as one input into an ongoing daily practice tend to change. The medicine is not a subscription service for enlightenment. It's a rare intervention that only pays off if you do the small, unglamorous work between doses. Practical integration looks like: Something people rarely admit: presence doesn't make the pain go away. It makes you able to be with it. There's a line worth remembering — a practitioner has every right to suffer, but not the right to skip the practice. Meaning: if you're a person working on yourself, you're allowed to hurt. You're allowed to be furious, grief-stricken, lost. But you don't get to let the pain drive the car anymore. This is the actual gift of both mindfulness and plant medicine. Not the absence of suffering — anyone selling that is selling snake oil — but a different relationship to it. You learn to stop running. You learn that when you sit down inside your own difficulty and stay there, breathing, the difficulty starts to reveal what it's been trying to tell you. This is where addiction begins to loosen its grip. This is where the trauma finally has room to be seen. Not because the substance forced it, but because you finally stopped sprinting away. Ayahuasca can bring the material to the surface. Ibogaine can interrupt the neurochemistry of a craving. Psilocybin can dissolve the rigid story you've been telling about yourself. But the work of staying — of not bolting the moment things get uncomfortable — that's yours. And it's a skill you build in ordinary time, with ordinary objects, one orange at a time. If all of this feels like a lot, start absurdly small. Tomorrow morning, when you first stand up, notice your feet on the floor. That's it. Three seconds. Then get on with your day. The morning after, do it again. Add the sensation of the water on your hands when you wash them. A week later, notice the first sip of coffee. Build the muscle. It grows faster than you'd think. Whether or not you ever sit in a ceremony, this practice will change your life. If you do sit in ceremony — and many readers here are seriously considering it — this practice will determine how much of the medicine actually reaches you and stays with you. For those weighing the decision and wanting to explore what's out there, a curated range of plant-medicine and psychedelic retreats can be browsed on our marketplace here. Take your time choosing. Then, before you go, start with the orange.
How to Describe an Ayahuasca Trip to Someone Who's Never Sat
Try it sometime. Sit across from a friend at a kitchen table and attempt to explain what actually happened during your ayahuasca ceremony. Watch their face. Watch yourself reach for words that don't exist in English, or in any language really, and then watch yourself settle for something that sounds either boring or unhinged. There's no middle ground. That's the first thing anyone who has drunk the brew learns — the experience resists translation the way a dream resists being retold at breakfast. And yet people keep asking. Friends, partners, parents, the coworker who overheard you say the word ayahuasca and now wants to know if you saw God. So this piece is for two kinds of readers: the person who's already been and can't find the language, and the person considering a psychedelic retreat who wants some honest sense of what they'd be walking into. Neither group will get a tidy answer. But we can get closer than the usual clichés about jungles and jaguars. Language is built for shared reference points. You describe a sunset and the listener pulls up their own memory of a sunset — job done. Ayahuasca doesn't have shared reference points. The visuals aren't like anything most people have seen. The emotional register isn't like anything most people have felt. And the sense that time has come off its hinges — that thirty seconds and thirty years can occupy the same breath — has no everyday analog to lean on. Neuroscientists studying DMT and other classic psychedelics talk about the default mode network quieting down, letting parts of the brain that don't usually chat with each other strike up long conversations. That's a plausible mechanism. It's also not what you say to your mother when she asks how the retreat went. The vocabulary of neuroscience is accurate and completely useless for capturing the felt sense of the thing. Most people fall back on one of three lazy shortcuts: it was like a really intense dream, it was like the strongest drug I've ever taken, or it was spiritual. All three are wrong in interesting ways. Dreams are private and slippery; ayahuasca often feels more real than waking life. Recreational drugs alter the sensorium; ayahuasca seems to be doing something to the self doing the sensing. And spiritual is a word so drained of meaning that it lands as either a red flag or a shrug, depending on the listener. When you spend enough time around people who've sat in ceremony, you start to notice the same handful of comparisons cycling through, each one useful for a different sliver of the experience. None of them cover the whole thing. Stacked together, they get you maybe forty percent of the way there. Notice that none of these are pleasant descriptions in the way a spa weekend is pleasant. Ayahuasca is not comfortable. People who market it as blissful are either selling something or they drank a weak cup. The physical container of a traditional ayahuasca ceremony is almost boring in its simplicity. You gather in a maloca or ceremony room at dusk. You drink a small cup of a bitter brown liquid that tastes, depending on the batch, like tar, licorice, or something scraped from a compost heap. You return to your mat. The lights go out. And then you wait, sometimes for forty minutes, sometimes for an hour and a half, for the medicine to arrive. When it does, it doesn't announce itself politely. The onset is often a kind of subtle wrongness in the room — the shadows get more interesting, sounds acquire texture, and then geometry begins to weave itself through your visual field whether your eyes are open or shut. The facilitators start singing icaros, the traditional songs that steer the ceremony, and those songs stop sounding like songs and start sounding like navigation instructions. From there, every ceremony is different. Some people spend six hours in a state of stunned tenderness, weeping quietly. Others meet their own worst memories head-on and have to be walked through them by a facilitator sitting patiently beside their mat. Some laugh. Some purge into a bucket and feel a decade of grief leave with it. Some, occasionally, get very little and feel cheated — until three days later when the material starts arriving in dreams. Here's the part most first-time descriptions skip. The ceremony ends. You sleep, sort of. You wake up and eat something bland. And you're a slightly different person. Not radically — you still know your PIN and your mother's birthday — but the internal weather has shifted. The most common report is a strange, quiet clarity. Things that felt urgent last week feel small. Things you'd been ignoring feel unignorable. Old resentments can lose their charge overnight, which is disorienting because your identity was partly built around them. Some people describe it as walking around with the volume of self-criticism turned down by about sixty percent. This is why integration matters, and why anyone considering a psychedelic retreat should ask hard questions about what happens after the last ceremony. The experience itself is the smaller part. The weeks and months of translating what you saw into how you live are the larger part. Retreats that hand you a certificate and a shuttle to the airport are not offering plant medicine work. They're offering a rough weekend with visuals. For readers who've already been and are struggling with the reentry conversation, a few practical suggestions from people who've had to do this a lot. You don't need to know exactly what ayahuasca feels like before you sit — you can't, and reading a hundred trip reports won't fix that. What you do need is a clear sense of why you're going, an honest read on your mental health history, and a facilitator or center you've properly vetted. Ask about medical screening. Ask about integration support. Ask what happens if you have a hard night. If the answers are vague or evangelistic, keep looking. The people who tend to get the most from plant medicine are the ones who arrive with a specific question and leave willing to let the answer be uncomfortable. It's not tourism. It's not a personality upgrade. It's a serious tool that occasionally helps serious problems shift in ways that years of ordinary effort couldn't manage — and it demands respect on the way in and patience on the way out. For readers who want to take this further, a range of vetted ayahuasca ceremonies and plant medicine retreats can be browsed on our marketplace here. Whatever you decide, decide slowly. This isn't the kind of thing you rush into on a Tuesday because your ex got engaged.
When Family Wounds Follow You Into Ceremony: Healing the Parent Story
There's a moment that happens for a lot of people mid-ceremony — usually somewhere in the second or third hour of an ayahuasca night, when the medicine has fully taken hold and the visuals have quieted into something more emotional than psychedelic. A face appears. Almost always, it's a parent. Sometimes both. Facilitators who've been holding space for decades will tell you the same thing: the mother wound and the father wound show up in the maloca more often than any other single theme. More than trauma flashbacks. More than fear of death. More than the classic ego dissolution stuff you read about online. What people actually meet, again and again, is the child version of themselves still waiting for something a parent never gave them. I want to talk about that — not from the ceremony side, but from the integration side. Because most of the real work with the parent wound doesn't happen during the drink. It happens in the weeks and months afterward, when you're back home, the phone rings, and you have to decide who you're going to be on that call. Ayahuasca, psilocybin, and to a lesser extent ibogaine and San Pedro all have this quality of stripping away the adult scaffolding we've built over our earliest hurts. The professional identity, the therapist-speak, the well-rehearsed story about our upbringing — the medicine tends to walk past all of it and sit you down opposite the eight-year-old you used to be. That kid usually has something to say. The reason for this isn't mystical, or at least not only mystical. Neuroscience research on psychedelics keeps pointing to the same mechanism: the brain's default mode network — the part responsible for narrative self, for the story of who you are — quiets down. When it quiets, the tight grip on the adult persona loosens, and older emotional material becomes accessible. That material is almost always relational, and the earliest relationships are almost always with parents. Which is why so much of what gets called "psychedelic healing" is actually family-of-origin work in a chemically accelerated form. The medicine doesn't invent the wound. It shows it to you in high resolution and asks what you're going to do about it now that you can no longer look away. Here's a scene I've heard some version of maybe fifty times from people I've interviewed after their retreats. They come home from Peru or Costa Rica or Jamaica feeling cracked open in the best possible way. They're eating better. Sleeping better. Their partner says they seem lighter. Then Mom calls. Or Dad. And within seven minutes they're seventeen years old again, tight in the chest, saying yes to things they don't want to say yes to, hanging up feeling smaller than they did before the phone rang. This is normal. It's also the actual work. Because the ceremony gave you a preview — a felt sense of what unconditional worth might be like when the noise stops. But the parent, in most cases, hasn't been to that ceremony. They're operating on the same script they've always used. And the script is powerful because it's older than your adult mind. It got installed before you had language to question it. One woman I spoke with after a series of psilocybin sessions put it this way: the medicine showed her she was lovable, and her mother had never gotten that memo, and probably never would. Sitting with that gap — the gap between what she now knew about herself and what her mother could offer — was harder than any ceremony. There's a word that gets misused a lot in psychedelic and Buddhist circles: detachment. People hear it and think it means going cold, cutting contact, becoming the kind of person who doesn't feel things about family anymore. That's not what it means. Not in the traditions the plants come from, and not in the wider contemplative world either. Detachment is closer to what happens when you finally understand that another person's behavior is not a referendum on your worth. Your father forgetting to ask about your trip to India isn't proof you're forgettable. Your mother repeating herself because of the wine and the antidepressants isn't proof you're not worth remembering. It's proof that they are carrying things they never dealt with, and those things are now sitting between you and them like fog. Master plants — the ayahuasca vine, huachuma, tobacco, chacruna, the mushroom lineages — teach this differently than a book can. In ceremony you often feel the difference between the story a parent told you about yourself and the actual, prior fact of your being. The story turns out to be one interpretation. The fact underneath is something else entirely. Once you've felt that, even briefly, the story loses some of its authority. If you're reading this because you're weighing a retreat — for addiction, for depression, for trauma, for the stuck feeling that has a lot to do with the family you grew up in — here are a few things worth knowing before you book anything. Let me be honest about something. Ayahuasca will not make your father a different man. Psilocybin will not sober your mother up. Ibogaine, extraordinary as it is for interrupting addiction patterns, cannot install empathy into people who don't want it. This is one of the harder truths about plant medicine and it doesn't get said often enough by the retreat marketing pages. What does change — and this is the part that matters — is your relationship to the story. The internal machinery that took every silence from a parent and translated it as you are not enough starts to lose its grip. You get slower to accept the translation. Eventually you stop accepting it altogether, most days. People I've followed over years after their retreat work describe it less as a dramatic healing and more as a quiet reorganization. They still love their parents. They call less, or they call the same amount but hang up with fewer bruises. They stop expecting apologies that aren't coming. They spend more energy on the relationships that actually feed them — friends, chosen family, partners who chose them freely — and less on the ones that were assigned by biology. If parent wounds and childhood trauma are the main reasons you're considering plant medicine, be a little pickier than you'd otherwise be about where you sit. Some things worth asking about when you're vetting a center: The parent wound is one of the most common reasons people come to plant medicine and one of the most rewarding places to do the work, but it deserves a container built for it. If you're looking to explore what's out there, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, remember the actual power isn't in the brew or the ceremony or the shaman. It's in the moment, weeks later, when the phone rings and you notice — just for a second — that you don't have to become small anymore. That noticing is the whole thing.
Inside the FDA's Psychedelics Hearing: What It Means for Future Access
Something unusual happened at the FDA's White Oak campus recently. Roughly three hundred people showed up in person — with another thousand watching online — for a rare public hearing on whether, and how, psychedelics might one day be approved as therapeutic drugs. If you've been following the slow, sometimes maddening march of psychedelics toward mainstream medicine, this was a moment worth paying attention to. These aren't your standard regulatory meetings. The FDA has only convened two of these so-called Part 15 hearings since 2020. They're informal, discretionary, and usually reserved for topics the agency considers to be in the public interest. Getting one for psychedelics is, in itself, a signal. Around eighty people delivered two-minute comments across the afternoon. Half in person. Half beamed in by video. The audience? Overwhelmingly people from inside the psychedelics field — researchers, clinicians, drug developers, veterans' advocates, and a fair number of true believers. If you were expecting a balanced roomful of skeptics and supporters, this wasn't it. The comments ranged widely, but a few themes kept surfacing. Provider training. Patient safety. Access. Data collection. None of it was groundbreaking for anyone who's been tracking this space — but the accumulation of voices, all pointing in similar directions, is telling in itself. One repeated plea: don't treat psychedelics as drugs that work in isolation. Speakers like Lawrence Leeman from the University of New Mexico pushed for the framing of psychedelic-assisted therapy, with real weight given to preparation and integration. Psychologist Geoff Bathje said he'd been disappointed to watch the agency downplay the therapeutic relationship in clinical trials, treating the drug effect as if it could be cleanly isolated from context. Here's the wrinkle, though. The FDA doesn't regulate psychotherapy. It regulates drugs. So even sympathetic staffers are working within a legal frame that wasn't built for what psychedelic treatment actually looks like in practice. Not everyone wanted mandatory psychotherapy baked into approvals. Peter Hendricks, a professor at the University of Alabama at Birmingham, argued that a blanket therapy requirement would hit hardest on people who already can't afford quality mental health care. Many patients in his trials, he pointed out, are low-income and uninsured. Requiring them to also access a licensed psychotherapist — often out of pocket — could effectively lock them out. His suggestion was cleaner: let the label specify which of three models the evidence actually supports. Safety monitoring. Psychological support. Or full-blown psychotherapy. Different molecules, different indications, different frameworks. Labels aren't just paperwork, by the way. Amna Aslam from Radial made the point that insurers build their coverage rules directly from what's on the label. Write it too narrowly, and reimbursement becomes a nightmare. Write it thoughtfully, and coverage might actually reach the people who need it. Another recurring theme was how restrictive the safety scaffolding around any approval should be. In FDA-speak, that's REMS — Risk Evaluation and Mitigation Strategies. Multiple speakers asked the agency to design REMS on a drug-by-drug basis, rather than slapping a single template across the whole psychedelic class. Lawrence Goldkind, a former FDA staffer himself, pushed for exactly this kind of tailoring. Advocates on this front will likely be pleased. From what we understand, a shared class-wide REMS is very unlikely, at least in the near term. The concern underneath all of this is access. Laurel Kilgour, speaking for the Psychedelic Bar Association, put it bluntly: an overly aggressive risk mitigation framework can actually undermine safety, because it pushes people toward underground alternatives with zero oversight. If the clinic route is impossibly gated, patients will find another route. They always do. Christian Reed, a retired Green Beret speaking on behalf of at-home ketamine company Mindbloom, took this argument even further. Don't lock this inside clinics in a handful of major cities, he told the panel. Don't weigh it down with so much overhead that insurers walk away. Not everyone was in a hurry. Eddie Jacobs, a researcher at Johns Hopkins, argued for a conservative initial rollout — what he called a safety floor anchored close to the trial context. Yes, he admitted, this will limit access at first. Yes, it puts extra weight on providers. But starting stronger and loosening as evidence accumulates, he said, is better than the reverse. Amber Barnato from Dartmouth — a certified psychedelic-assisted therapy facilitator herself — called FDA approval of psychedelics “ethically defensible” but flagged that the underlying evidence is of low certainty. Small trials. Functionally unblinded designs. Her fix was to build ongoing comparative effectiveness studies via registries that actually track things consistently: patients' intentions, expectations, the quality of preparation and integration. Right now, she said, those are captured haphazardly across trials, when they're captured at all. Then there was Susan Taymor Sagy, whose 21-year-old daughter died following psychedelic use. Her comment cut through the room. Public education, she told the panel, cannot be an afterthought. An FDA approval carries enormous cultural weight, and the messaging around it needs to reflect that. Only one speaker showed up as an outright critic: Kevin Sabet, a familiar figure in drug policy debates. He joined virtually, despite being listed to attend in person. He opened by pointing out he had no financial disclosures to make — a barbed reference, presumably, to the many speakers who did. Psychedelics, Sabet argued, should earn approval through science and trials, not through politics or podcasters. He hit the studies for small sample sizes and methodological weaknesses. He also seemed to gesture at Americans for Ibogaine co-founder Bryan Hubbard, who had recently invoked JFK's line about how those who make peaceful revolution impossible make violent revolution inevitable — while advocating for ibogaine access at a veterans' convention. Whatever you think of Sabet's politics, his was one of very few voices at the hearing not cheering the process forward. The rest of the room, as one attendee described it, felt at times a bit self-congratulatory. The moderator asked people twice not to applaud. A few clapped anyway. Most comments focused on mental health indications — depression, PTSD, addiction, the usual suspects. But a small chorus tried to widen the frame. Speakers from Clusterbusters, the Psychedelics and Pain Association, and Cy Biopharma discussed psychedelics for pain, particularly for something like cluster headache, where the standard trial design might not even fit. Cluster headache patients often benefit from sub-perceptual or low doses rather than the full ceremonial experience. One cochlear implant recipient even suggested psychedelics might help patients accelerate the neural learning curve required to make sense of the device. Whether that gets any regulatory traction is another question — but it's a good reminder that the therapeutic possibilities here don't stop at psychiatry. The most striking part of the whole afternoon may have been what didn't happen. In previous Part 15 hearings, back-and-forth between the federal panel and commenters is a normal feature of proceedings. Microphones had been placed in front of each of the nine panellists. The agenda allowed for it. Speakers even rattled through their two-minute slots ahead of schedule, leaving time to spare. And yet, aside from opening remarks, not a single panellist asked a question. Not one word. That silence is what leaves people in the field guessing. What does the FDA actually want to know? What are its private concerns? Which comments landed and which slid past unnoticed? The format didn't reveal any of it — a conveyor belt of two-minute pitches, absorbed in stone-faced quiet by the people who'll eventually write the rules. If you're reading this because you're weighing whether plant medicine or a psychedelic retreat might help with something you're carrying — depression, addiction, trauma, a life pattern you can't seem to break — the takeaway is a mixed one. The regulatory path in the U.S. is inching forward. Slowly. With real disagreement inside the field about what safe access should look like. What it isn't yet is a system you can walk into and get reimbursed for. And even after approvals arrive, the clinical model — dosing in a sterile room, minimal preparation, limited integration — may look very different from what people describe finding in a well-run ceremonial retreat. The debate at White Oak was, in a way, an argument about how much of the ceremonial and relational context to preserve when the medicine gets professionalised. If you want to explore what's already available in the current landscape — legitimate, well-facilitated ayahuasca ceremonies, psilocybin retreats, ibogaine programs for addiction, and other plant-medicine offerings — a curated selection of retreats can be browsed on our marketplace here. Whatever the FDA eventually decides, the older traditions aren't waiting on Washington, and for many people that's exactly the point.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
